There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avidity Biosciences (RNA – Research Report) and Springworks Therapeutics (SWTX – Research Report) with bullish sentiments.
Avidity Biosciences (RNA)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Avidity Biosciences, with a price target of $35.00. The company’s shares closed last Tuesday at $7.32, close to its 52-week low of $4.83.
According to TipRanks.com, Stringer has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Avidity Biosciences is a Strong Buy with an average price target of $31.50, representing a 308.0% upside. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $23.00 price target.
See the top stocks recommended by analysts >>
Springworks Therapeutics (SWTX)
TD Cowen analyst Yaron Werber maintained a Buy rating on Springworks Therapeutics today. The company’s shares closed last Tuesday at $25.25.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Currently, the analyst consensus on Springworks Therapeutics is a Strong Buy with an average price target of $55.67, implying a 142.0% upside from current levels. In a report issued on November 16, Goldman Sachs also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RNA:
- Bristol-Myers (NYSE:BMY) Expands Collaboration with Avidity Bio in $2.3B Deal
- Avidity Biosciences reports Q3 EPS (71c), consensus (77c)
- Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
- Avidity Biosciences announces AOC 1001 data from MARINA trial, MARINA-OLE study
